Bio-Techne Replaces Diagnostics Chief, Names Steve Crouse to Lead $1.2M Role

Bio-Techne Corporation (NASDAQ: TECH) announced a leadership transition in its Diagnostics and Spatial Biology Segment, with Dr. Matt McManus departing his role as segment president effective March 1, 2026. The company has named Steve Crouse, currently Senior Vice President of the Analytical Solutions Division, as his successor.

The Change

The transition marks a significant shift for Bio-Techne's diagnostics business, with McManus being terminated without cause according to the SEC filing. He will receive severance benefits per his employment agreement and remain with the company temporarily to ensure a smooth transition.

Crouse, 52, will assume the role with a comprehensive compensation package totaling approximately $2.1 million annually. His base salary will be $505,000, with a target annual bonus of 75% of base salary ($378,750). Additionally, he received a one-time equity grant worth $170,000 and will receive annual equity awards valued at $1.2 million, split between time-vested stock options ($300,000), time-vested restricted stock units ($300,000), and performance-based restricted stock units ($600,000 at target).

The employment agreement, signed February 10, 2026, includes standard executive protections. If terminated without cause or for good reason, Crouse would receive one year of base salary, prorated bonus, and health insurance coverage.

Background

Crouse brings significant industry experience to the role, having spent four years at Bio-Techne leading the Analytical Solutions Division. In that position, he managed the company's protein analysis instruments and immunoassays portfolio, successfully launching several innovative platforms while delivering strong growth.

His resume includes a previous role as General Manager of Thermo Fisher Scientific's Protein Detection and Quantification business unit, one of the industry's leading positions in analytical instruments. Crouse holds an MBA from the University of Southern California's Marshall School of Business and a Master of Science in Biochemistry from Georgetown University.

The Diagnostics and Spatial Biology Segment represents a critical growth area for Bio-Techne, particularly as the company expands its presence in spatial biology—an emerging field that allows researchers to analyze gene and protein expression within intact tissue samples. This technology has become increasingly important for cancer research and drug development.

What It Means

The leadership change signals Bio-Techne's commitment to accelerating growth in its diagnostics division through internal talent promotion. By selecting Crouse, who has already demonstrated success within the organization, the company avoids the typical 6-12 month learning curve associated with external hires.

The substantial equity component of Crouse's compensation package—representing 70% of his total annual compensation—aligns his interests with shareholder returns. The performance-based restricted stock units, worth $600,000 at target and vesting over three years based on fiscal 2026-2028 performance goals, create strong incentives for delivering results.

For investors, the smooth internal succession suggests operational continuity. Crouse's background in protein analysis instruments positions him well to lead a segment increasingly focused on sophisticated diagnostic platforms. His experience at Thermo Fisher, a $40 billion life sciences giant, provides valuable perspective on scaling diagnostic businesses.

The timing of the transition, effective March 1 with McManus remaining temporarily, minimizes disruption during Bio-Techne's fiscal third quarter. This approach allows for knowledge transfer while maintaining business momentum.

The segment Crouse will lead operates in the rapidly growing spatial biology market, projected to reach $1.2 billion by 2027 according to industry estimates. His technical background in biochemistry and protein detection aligns well with the segment's focus on advanced diagnostic technologies.

While the filing doesn't specify reasons for McManus's departure, the termination without cause designation and severance package suggest an amicable separation focused on strategic realignment rather than performance issues.